SAFETY DATA SHEET

Ezetimibe / Atorvastatin Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Ezetimibe / Atorvastatin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   117 16th Road
   07033 Halfway house, Midrand, South Africa
   Telephone : +27 11 655 3000
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Specific target organ toxicity - repeated exposure, Category 2
   Long-term (chronic) aquatic hazard, Category 2
   H373: May cause damage to organs through prolonged or repeated exposure.
   H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 🔴 ⬤
   Signal word : Warning
   Hazard statements : H373 May cause damage to organs through prolonged or repeated exposure.
                      H411 Toxic to aquatic life with long lasting effects.
   Precautionary statements : Prevention:
                            P260 Do not breathe dust.
P273 Avoid release to the environment.

Response:
P314 Get medical advice/attention if you feel unwell.
P391 Collect spillage.

Hazardous components which must be listed on the label:
Atorvastatin

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>134523-03-8</td>
<td>134523-03-8</td>
<td></td>
<td>STOT RE2; H373 Aquatic Chronic2; H411</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>163222-33-1</td>
<td></td>
<td>Aquatic Chronic1; H410</td>
<td>&gt;= 2.5 - &lt; 10</td>
</tr>
</tbody>
</table>

M-Factor (Chronic aquatic toxicity): 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed:
- If swallowed, DO NOT induce vomiting.
- Get medical attention if symptoms occur.
- Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks:
- May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.
- Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment:
- Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Nitrogen oxides (NOx)
- Fluorine compounds
- Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

**Hygiene measures**
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 **Conditions for safe storage, including any incompatibilities**

**Requirements for storage areas and containers**
- Keep in properly labelled containers. Store in accordance with the particular national regulations.

**Advice on common storage**
- Do not store with the following product types:
  - Strong oxidizing agents

7.3 **Specific end use(s)**

**Specific use(s)**
- No data available

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA OEL-RL (Respirable dust)</td>
<td>5 mg/m³</td>
<td>ZA OEL</td>
</tr>
<tr>
<td>Further information</td>
<td>Recommended Limit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA OEL-RL (Inhalable dust)</td>
<td>10 mg/m³</td>
<td>ZA OEL</td>
</tr>
<tr>
<td>Further information</td>
<td>Recommended Limit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL OEL-RL (Dust)</td>
<td>20 mg/m³</td>
<td>ZA OEL</td>
</tr>
<tr>
<td>Further information</td>
<td>Recommended Limit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>134523-03-8</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.5 mg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

#### 8.2 Exposure controls

**Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Personal protective equipment**

**Eye protection**
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**
- Material: Chemical-resistant gloves
- Remarks: Consider double gloving.

**Skin and body protection**
- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type: Particulates type (P)

---

**SECTION 9: Physical and chemical properties**

9.1 **Information on basic physical and chemical properties**

- **Appearance**: powder
- **Colour**: off-white
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: Not applicable
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
SAFETY DATA SHEET

Ezetimibe / Atorvastatin Formulation

Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : No data available
Solubility(ies)
   Water solubility : 0.01 g/l
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
   Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids) : No data available
Molecular weight : No data available
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.
SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**
Not classified based on available information.

**Components:**

**Atorvastatin:**
- Acute oral toxicity: LD50 (Rat, male and female): > 5.000 mg/kg
  LD50 (Mouse, male and female): > 5.000 mg/kg

**Ezetimibe:**
- Acute oral toxicity: LD50 (Rat): > 5.000 mg/kg
  LD50 (Mouse): > 5.000 mg/kg
  LD50 (Dog): > 3.000 mg/kg
- Acute inhalation toxicity: Remarks: No data available
- Acute dermal toxicity: Remarks: No data available
- Acute toxicity (other routes of administration): LD50 (Rat): > 2.000 mg/kg
  Application Route: Intraperitoneal
  LD50 (Mouse): > 1.000 - < 2.000 mg/kg
  Application Route: Intraperitoneal

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Atorvastatin:**
- Species: Rabbit
  Result: No skin irritation

**Ezetimibe:**
- Species: Rabbit
  Result: No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.
Components:

Atorvastatin:
Species: Rabbit  
Method: Draize Test  
Result: No eye irritation

Ezetimibe:
Species: Rabbit  
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Atorvastatin:
Test Type: Maximisation Test  
Exposure routes: Skin contact  
Species: Guinea pig  
Result: negative

Ezetimibe:
Test Type: Maximisation Test  
Species: Guinea pig  
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Atorvastatin:
Genotoxicity in vitro:  
Test Type: reverse mutation assay  
Test system: Salmonella typhimurium  
Result: negative

Test Type: reverse mutation assay  
Test system: Escherichia coli  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: sister chromatid exchange assay  
Test system: Chinese hamster lung cells  
Result: negative
SAFETY DATA SHEET

Ezetimibe / Atorvastatin Formulation

Genotoxicity in vivo
- Test Type: In vivo micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Oral
  - Result: negative

Ezetimibe:
Genotoxicity in vitro
- Test Type: Bacterial reverse mutation assay (AMES)
  - Metabolic activation: with and without metabolic activation
  - Result: negative
- Test Type: Chromosomal aberration
  - Test system: Human lymphocytes
  - Result: negative

Genotoxicity in vivo
- Test Type: Micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Oral
  - Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Atorvastatin:
- Species: Mouse, male and female
- Application Route: oral (gavage)
- Exposure time: 2 Years
- NOAEL: 200 mg/kg body weight
- LOAEL: 400 mg/kg body weight
- Result: negative
- Target Organs: Liver

- Species: Rat, female
  - Application Route: oral (gavage)
  - Exposure time: 2 Years
  - LOAEL: 100 mg/kg body weight
  - Target Organs: Musculo-skeletal system

Ezetimibe:
- Species: Rat, female
  - Application Route: oral (feed)
  - Exposure time: 104 weeks
  - Result: negative

- Species: Rat, male
  - Application Route: oral (feed)
  - Exposure time: 104 weeks
  - Result: negative
Reproductive toxicity
Not classified based on available information.

Components:

Atorvastatin:
Effects on fertility
- Test Type: Fertility/early embryonic development
- Species: Rat, female
- Fertility: NOAEL: 225 mg/kg body weight
- Result: No effects on fertility
- Test Type: Fertility/early embryonic development
- Species: Rat, male
- Fertility: NOAEL: 175 mg/kg body weight
- Result: No effects on fertility

Effects on foetal development
- Species: Rat, female
- Developmental Toxicity: NOAEL: 20 mg/kg body weight
- Result: No teratogenic effects, Embryo-foetal toxicity
- Remarks: Maternal toxicity observed.
- Species: Rabbit, female
- Application Route: Oral
- Developmental Toxicity: NOAEL: 100 mg/kg body weight
- Result: No embryo-foetal toxicity

Ezetimibe:
Effects on fertility
- Test Type: Fertility/early embryonic development
- Species: Rat, male and female
- Fertility: NOAEL: > 1.000 mg/kg body weight
- Result: No effects on fertility, No fetotoxicity

Effects on foetal development
- Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight
- Result: No adverse effects
- Test Type: Development
- Species: Rabbit
- Application Route: Oral
- Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight
- Result: No adverse effects

STOT - single exposure
Not classified based on available information.
STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Atorvastatin:
Exposure routes: Ingestion
Target Organs: Liver, muscle
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Atorvastatin:
Species: Rat, male and female
LOAEL: 70 mg/kg
Application Route: oral (gavage)
Exposure time: 52 Weeks
Target Organs: Liver

Species: Dog
LOAEL: 10 mg/kg
Application Route: oral (gavage)
Exposure time: 104 Weeks
Target Organs: Liver

Ezetimibe:
Species: Dog
NOAEL: 1,000 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 1,500 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 500 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 300 mg/kg
Application Route: Oral
Exposure time: 1 yr
Remarks: No significant adverse effects were reported
Aspiration toxicity
Not classified based on available information.

Components:

Ezetimibe:
Not applicable

Experience with human exposure

Components:

Atorvastatin:
Ingestion: Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change

Ezetimibe:
Ingestion: Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

SECTION 12: Ecological information

12.1 Toxicity

Components:

Atorvastatin:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 92 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 200 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 14 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms: EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity): NOEC: 0,49 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 0.2 mg/l
- Exposure time: 21 d
- Species: Daphnia magna (Water flea)
- Method: OECD Test Guideline 211

Ezetimibe:
- Toxicity to fish:
  - LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
  - Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates:
  - EC50 (Daphnia magna (Water flea)): > 4 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - Remarks: No toxicity at the limit of solubility
- Toxicity to algae/aquatic plants:
  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility
  - NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms:
- EC50: > 4.4 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - Remarks: No toxicity at the limit of solubility
  - NOEC: 4.4 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):
- NOEC: 0.051 mg/l
  - Exposure time: 33 d
  - Species: Pimephales promelas (fathead minnow)
  - Method: OECD Test Guideline 210
  - NOEC: 4 mg/l
  - Exposure time: 7 d
  - Species: Cyprinodon variegatus (sheepshead minnow)
  - Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 0.282 mg/l
  - Exposure time: 21 d
  - Species: Daphnia magna (Water flea)
  - Remarks: No toxicity at the limit of solubility
12.2 Persistence and degradability

**Components:**

**Atorvastatin:**

**Ezetimibe:**
Biodegradability: Result: Not readily biodegradable. Biodegradation: 6.8 % Exposure time: 28 d

Stability in water: Hydrolysis: 50 % (4.5 d) Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

**Components:**

**Atorvastatin:**
Partition coefficient: n-octanol/water: log Pow: 1.62

**Ezetimibe:**
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish) Exposure time: 97 d Bioconcentration factor (BCF): 173 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.36

12.4 Mobility in soil

**Components:**

**Atorvastatin:**
Distribution among environmental compartments: log Koc: 2.84

**Ezetimibe:**
Distribution among environmental compartments: log Koc: 4.35 Method: OECD Test Guideline 106

12.5 Results of PBT and vPvB assessment

Not relevant
12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name
ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
IATA : Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Atorvastatin)

14.3 Transport hazard class(es)
ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9
14.4 Packing group

**ADN**
- Packing group: III
- Classification Code: M7
- Hazard Identification Number: 90
- Labels: 9

**ADR**
- Packing group: III
- Classification Code: M7
- Hazard Identification Number: 90
- Labels: 9
- Tunnel restriction code: (-)

**RID**
- Packing group: III
- Classification Code: M7
- Hazard Identification Number: 90
- Labels: 9

**IMDG**
- Packing group: III
- Labels: 9
- EmS Code: F-A, S-F

**IATA (Cargo)**
- Packing instruction (cargo aircraft): 956
- Packing instruction (LQ): Y956
- Packing group: III
- Labels: Miscellaneous

**IATA (Passenger)**
- Packing instruction (passenger aircraft): 956
- Packing instruction (LQ): Y956
- Packing group: III
- Labels: Miscellaneous

14.5 Environmental hazards

**ADN**
- Environmentally hazardous: yes

**ADR**
- Environmentally hazardous: yes

**RID**
- Environmentally hazardous: yes

**IMDG**
- Marine pollutant: yes

**IATA (Passenger)**
- Environmentally hazardous: yes

**IATA (Cargo)**
- Environmentally hazardous: yes
SAFETY DATA SHEET

Ezetimibe / Atorvastatin Formulation

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
The components of this product are reported in the following inventories:

AICS: not determined

DSL: not determined

IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H373: May cause damage to organs through prolonged or repeated exposure if swallowed.

H410: Very toxic to aquatic life with long lasting effects.

H411: Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Chronic: Long-term (chronic) aquatic hazard
STOT RE: Specific target organ toxicity - repeated exposure
ZA OEL: South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits
ZA OEL / TWA OEL-RL: Long term occupational exposure limits - recommended limit
ZA OEL / STEL OEL-RL: Short term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System;
Further information

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
- STOT RE 2 H373 Calculation method
- Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.